United Therapeutics (NASDAQ:UTHR) CEO Sells $5,231,650.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $550.70, for a total transaction of $5,231,650.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $178,670,760.10. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

United Therapeutics Stock Up 0.3%

Shares of UTHR stock opened at $541.51 on Friday. The firm has a market cap of $23.23 billion, a P/E ratio of 19.37, a PEG ratio of 3.86 and a beta of 0.49. The company has a 50 day moving average of $513.75 and a 200-day moving average of $540.45. United Therapeutics Corporation has a 12-month low of $409.07 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.41 EPS. As a group, equities analysts expect that United Therapeutics Corporation will post 26.40 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on UTHR. Bank of America lowered their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of United Therapeutics in a research report on Thursday, October 1st. JPMorgan Chase & Co. increased their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Finally, The Goldman Sachs Group reiterated a “sell” rating and issued a $368.00 target price on shares of United Therapeutics in a research note on Thursday. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $642.69.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Toth Financial Advisory Corp increased its position in shares of United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 48 shares during the period. Fiduciary Financial Advisors purchased a new stake in shares of United Therapeutics in the second quarter worth about $30,000. Caitlin John LLC bought a new position in shares of United Therapeutics in the second quarter valued at approximately $37,000. International Assets Investment Management LLC boosted its position in shares of United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 64 shares during the period. Finally, Keating Financial Advisory Services Inc. bought a new position in shares of United Therapeutics in the second quarter valued at approximately $81,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics settled all six patent and antitrust disputes with Liquidia, reducing litigation uncertainty surrounding Liquidia’s YUTREPIA inhaled treprostinil treatment. The agreement also limits YUTREPIA’s label, particularly by excluding the pulmonary hypertension associated with interstitial lung disease indication, which may protect UTHR’s competitive position. United Therapeutics Settles Litigation And Resets Pulmonary Hypertension Competition
• Positive Sentiment: The settlement calls for Liquidia to make approximately $380.7 million in payments, providing United Therapeutics with financial compensation for resolving the disputes. The deal also gives investors more visibility into the future competitive landscape. LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
• Positive Sentiment: Jefferies raised its price target for United Therapeutics to $728. Other analysts also remain constructive: the stock carries a “Moderate Buy” consensus rating and an average target of $627.31, above the recent trading level. UTHR Price Target Raised to $728 at Jefferies
• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.13 million, reducing her ownership by 2.84%. The transaction was disclosed in an SEC filing, but the remaining stake is substantial and the sale alone does not establish a change in business outlook. United Therapeutics CEO Stock Sale SEC Filing

About United Therapeutics

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.